KYTOPEN CORP
Automated platform for scalable genome engineering and cell therapy manufacturing
- Sector
- Biotech
- Headquarters
- Cambridge, MA
- Founded
- 2017
- Latest Form D
- $7.1M, Feb 2025
- Total capital
- $55.8M
- Federal grants
- $3.1M
- 5 awards · 2017–2025
- Rank in peer group#11 of 18
- Private capital raised
- $52.7M
- 5 Form D · last Feb 2025
- 20 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential$1M
- Private capital raisedForm D · SEC · 5th filing$7.1M
- Federal grantHealth and Human S · Phase II · Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential$582K
- Private capital raisedForm D · SEC · 4th filing$5.7M
- Private capital raisedForm D · SEC · 3rd filing$32.5M
- Federal grantHealth and Human S · Phase I · Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential$300K
- Private capital raisedForm D · SEC · 2nd filing$3.1M
- Private capital raisedForm D · SEC · 1st filing$4.3M
Show 2 earlier federal awards
- Federal grantNSF · Phase II · SBIR Phase II: An Automated Platform for Rapid Discovery in Cell Biology$948K
- Federal grantNSF · Phase I · SBIR Phase I: A scalable high-throughput cell engineering platform$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
17months
from KYTOPEN CORP’s first federal award to its first private round.
- First federal award · Dec 2017
- NSF · $225K
- First Form D · May 2019
- $4.3M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 18 peers
Line = medianBiotech · Device
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Michael ChiuResearcherDirector, Executive OfficerLinked by $1.6M in grants as PI
- Paulo GarciaResearcherExecutive Officer, Director, PromoterLinked by $1.5M in grants as PI
- Adam WieschhausDirectorNamed in SEC Form D filings
- Ann DeWittDirectorNamed in SEC Form D filings
- Bethany GrantExecutive OfficerNamed in SEC Form D filings
- Cullen BuieDirectorNamed in SEC Form D filings
Show all 11 people
- Edward FreedmanDirectorNamed in SEC Form D filings
- Julio VegaExecutive OfficerNamed in SEC Form D filings
- Paul WottonDirectorNamed in SEC Form D filings
- Paxton MajorDirectorNamed in SEC Form D filings
- Theresa TribbleDirectorNamed in SEC Form D filings
What it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- T3S Technologies, Inc.Similar federal contract value in Biotech · null in contracts
- ADVANTAGENE, INCSimilar federal contract value in Biotech · null in contracts
- Wise Trading Technologies, Inc.Similar federal contract value in Biotech · null in contracts
- WNTRIX INCSimilar federal contract value in Biotech · null in contracts
- Cogent BiosciencesSimilar federal contract value in Biotech · null in contracts
- VAXNEWMO, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .